Your browser doesn't support javascript.
loading
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies.
Yamamoto, Noboru; Ryoo, Baek-Yeol; Keam, Bhumsuk; Kudo, Masatoshi; Lin, Chia-Chi; Kunieda, Futoshi; Ball, Howard A; Moran, Diarmuid; Komatsu, Kanji; Takeda, Kentaro; Fukuda, Musashi; Furuse, Junji; Morita, Satoshi; Doi, Toshihiko.
Afiliação
  • Yamamoto N; Department of Experimental Therapeutics, Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. nbryamam@ncc.go.jp.
  • Ryoo BY; Department of Oncology, Asan Medical Center, University of Ulsan, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
  • Keam B; Department of Internal Medicine, Seoul National University Hospital, 101, Daehak-ro Jongno-gu, Seoul, 03080, Republic of Korea.
  • Kudo M; Department of Gastroenterology and Hepatology, School of Medicine, Kindai University, 3-4-1 Kowakae, Higashiosaka City, Osaka, 577-8502, Japan.
  • Lin CC; Department of Oncology, National Taiwan University Hospital, 7 Chung Shan S Rd, Taipei, 10002, Taiwan.
  • Kunieda F; Medical Science Oncology, Astellas Pharma Global Development, Inc., 1 Astellas Way, Northbrook, IL, 60062, USA.
  • Ball HA; Clinical Pharmacology & Exploratory Development - Oncology, Astellas Pharma Global Development, Inc., 1 Astellas Way, Northbrook, IL, 60062, USA.
  • Moran D; Clinical Pharmacology & Exploratory Development - Oncology, Astellas Pharma Global Development, Inc., 1 Astellas Way, Northbrook, IL, 60062, USA.
  • Komatsu K; Clinical Pharmacology, Astellas Pharma, Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan.
  • Takeda K; Data Science, Astellas Pharma Global Development, Inc., 1 Astellas Way, Northbrook, IL, 60062, USA.
  • Fukuda M; Japan-Asia Data Science, Astellas Pharma, Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan.
  • Furuse J; Department of Medical Oncology, Kyorin University School of Medicine, Faculty of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo, 181-8611, Japan.
  • Morita S; Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, sakyo-ku, Kyoto, 606-8501, Japan.
  • Doi T; Experimental Therapeutics of Digestive Endoscopy/Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba, 277-8577, Japan.
Invest New Drugs ; 38(2): 445-456, 2020 04.
Article em En | MEDLINE | ID: mdl-31041575
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Neoplasias Urológicas / Receptores de Fatores de Crescimento de Fibroblastos / Neoplasias de Células Escamosas / Carcinoma Hepatocelular / Neoplasias Hepáticas / Neoplasias Pulmonares / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Neoplasias Urológicas / Receptores de Fatores de Crescimento de Fibroblastos / Neoplasias de Células Escamosas / Carcinoma Hepatocelular / Neoplasias Hepáticas / Neoplasias Pulmonares / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article